The CXCR4 Antagonist AMD3100 Has Dual Effects on Survival and Proliferation of Myeloma Cells In Vitro

PURPOSE: AMD3100, an antagonist of the CXCR4 chemokine receptor is soon to be used clinically for the peripheral mobilization of hematopoietic stem cells (HSCs) in patients with multiple myeloma. AMD3100 has been shown to activate a G protein coupled with CXCR4 and thus acts as a partial CXCR4 agoni...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ha-Yon, Hwang, Ji-Young, Kim, Seong-Woo, Lee, Hyo-Jin, Yun, Hwan-Jung, Kim, Samyong, Jo, Deog-Yeon
Formato: Texto
Lenguaje:English
Publicado: Korean Cancer Association 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021742/
https://www.ncbi.nlm.nih.gov/pubmed/21253325
http://dx.doi.org/10.4143/crt.2010.42.4.225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021742/
https://www.ncbi.nlm.nih.gov/pubmed/21253325
http://dx.doi.org/10.4143/crt.2010.42.4.225

Ejemplares similares